Answers are grounded in this paper and cite their sources.
Randomized trial evaluates West Nile virus-neutralizing plasma effects on cognitive outcomes in patients, indicating potential benefits despite no change in death rates.
In this small, randomized trial of predominantly severe neuroinvasive WNV, treatment with WNV-neutralizing plasma did not reduce the composite outcome of death or functional deterioration at 30 days compared to placebo. It was associated with improved cognitive and functional outcomes. Potential differences in mortality warrant further evaluation. (ClinicalTrials.gov number, NCT06590207.).
No takes yet. Share an insight, caveat, or question.
Regev-Yochay et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: